MR-link-2: pleiotropy robust cis Mendelian randomization validated in three independent reference datasets of causality
- PMID: 40610416
- PMCID: PMC12229666
- DOI: 10.1038/s41467-025-60868-1
MR-link-2: pleiotropy robust cis Mendelian randomization validated in three independent reference datasets of causality
Abstract
Mendelian randomization (MR) identifies causal relationships from observational data but has increased Type 1 error rates (T1E) when genetic instruments are limited to a single associated region, a typical scenario for molecular exposures. We developed MR-link-2, which leverages summary statistics and linkage disequilibrium (LD) to estimate causal effects and pleiotropy in a single region. We compare MR-link-2 to other cis MR methods: i) In simulations, MR-link-2 has calibrated T1E and high power. ii) We reidentify metabolic reactions from three metabolic pathway references using four independent metabolite quantitative trait locus studies. MR-link-2 often (76%) outperforms other methods in area under the receiver operator characteristic curve (AUC) (up to 0.80). iii) For canonical causal relationships between complex traits, MR-link-2 has lower per-locus T1E (0.096 vs. min. 0.142, at 5% level), identifying all but one of the true causal links, reducing cross-locus causal effect heterogeneity to almost half. iv) Testing causal direction between blood cell compositions and marker gene expression shows MR-link-2 has superior AUC (0.82 vs. 0.68). Finally, analyzing causality between metabolites not directly connected by canonical reactions, only MR-link-2 identifies the causal relationship between pyruvate and citrate ( = 0.11, P = 7.2⋅10-7), a key citric acid cycle reaction. Overall, MR-link-2 identifies pleiotropy-robust causality from summary statistics in single associated regions, making it well suited for applications to molecular phenotypes.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: The main authors of this study do not declare a competing interest. The authors of the eQTLGen consortium declare the following competing interests: B.M.P. serves on the Steering Committee for the Yale Open Data Access Project funded by Johnson & Johnson. This activity is unrelated to this work. M.I. is a trustee of the Public Health Genomics (PHG) Foundation, a member of the Scientific Advisory Board of Open Targets, and has a research collaboration with AstraZeneca that is unrelated to this study. D.S.P. is an employee and stockholder of AstraZeneca. The other authors of the eQTLGen consortium do not declare competing interests.
Figures
References
-
- Katan, M. Apoupoprotein E isoforms, serum cholesterol, and cancer. Lancet327, 507–508 (1986). - PubMed
-
- Smith, G. D. & Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J. Epidemiol.32, 1–22 (2003). - PubMed
-
- Ference, B. A. et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J. Am. Coll. Cardiol.60, 2631–2639 (2012). - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
